Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company specializing in bicyclic peptide technology, has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, which will be followed by a Q&A breakout session at 5:35 p.m. PT.

Investors and interested parties can access a live webcast of the presentation through the Investor section of Bicycle Therapeutics' website at www.bicycletherapeutics.com. The company will also make a replay of the webcast available on their website after the event.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle^®) technology, today announced that management will participate at the 43^rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a question-and-answer breakout session at 5:35 p.m. PT.

A live webcast of the presentation will be accessible from the Investor section of the company’s website at www.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event.

About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle^® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle^® Toxin Conjugate (BTC^®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist^® (Bicycle TICA^®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle Radionuclide Conjugates (BRC^®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle^® technology to develop therapies for diseases beyond oncology.

Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit www.bicycletherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250109465188/en/

Investors:

Stephanie Yao

SVP, Investor Relations and Corporate Communications

stephanie.yao@bicycletx.com

857-523-8544

Matthew DeYoung

Argot Partners

ir@bicycletx.com

212-600-1902

Media:

Jim O’Connell

Weber Shandwick

media@bicycletx.com

312-988-2343

Source: Bicycle Therapeutics plc

FAQ

When is Bicycle Therapeutics (BCYC) presenting at the J.P. Morgan Healthcare Conference?

Bicycle Therapeutics is presenting on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a Q&A session at 5:35 p.m. PT.

How can investors watch Bicycle Therapeutics' (BCYC) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a live webcast available on the Investor section of Bicycle Therapeutics' website at www.bicycletherapeutics.com.

Will there be a replay available of Bicycle Therapeutics' (BCYC) J.P. Morgan presentation?

Yes, a replay of the webcast will be archived and available on Bicycle Therapeutics' website following the event.

What is the format of Bicycle Therapeutics' (BCYC) presentation at the J.P. Morgan Healthcare Conference?

The format includes a podium presentation followed by a question-and-answer breakout session, with the presentation starting at 5:15 p.m. PT and the Q&A session at 5:35 p.m. PT.